WEX Pharmaceuticals Inc .
They are focused on the development and commercialization of innovative drug products, primarily for pain management.
This company is dedicated to the discovery, development, manufacture and marketing of a new class of therapeutics to treat acute and chronic pain. They are devoting to developing a new class of non-opioid analgesics. The Company’s proprietary platform is Tetrodotoxin (TTX), a highly selective sodium channel blocker. WEX’s lead product based on TTX is in Phase III clinical development for the treatment of cancer related pain and in Phase II for chemotherapy induced neuropathic pain.
Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |
WEX Pharmaceuticals Inc .Suite 420 - 1090 West Pender Street |
Share with friends:
Nanotechnology in medicine | Nano materials | Nanotechnology electronics | Nano asociation |
Follow Nanotechnology Journal on
© 2008 - 2020 Nanotechnology research | All rights reserved | Developed by Makovic.net